John Taylor

Biography

 John is the founding CEO of Spyryx, leading the effort to form the Company into a therapeutic development organization targeting severe pulmonary indications. This entrepreneurial role relies heavily on his prior experience in biopharmaceutical business and corporate development, where he was responsible for execution of transactions valued in excess of $500 million. In addition to Spyryx, John has provided leadership to several other biopharmaceutical start-ups, including JUNCTIONRx, a company he founded to pursue orphan drug development. Previously, John was Vice President of Corporate Development at Synageva BioPharma (acquired by Alexion Pharmaceuticals), a biotechnology company focused on protein therapeutics for rare diseases, which he helped to take public via a reverse merger with Trimeris.  Prior to joining Synageva, John was the Vice President, Business Development for Javelin Pharmaceuticals, a clinical and commercial stage company developing treatments for acute pain.  Earlier in his career John held positions of increasing responsibility in licensing and business development, marketing, and sales with Eurand Pharma, Sarnoff Corporation, Amersham Pharmacia Biotech and BioWhittaker.

Research Interest

 Biology and Pharma